Anteris is still a development-stage structural-heart company building the DurAVR transcatheter heart valve toward commercialization, with manufacturing capacity being expanded to support the PARADIGM clinical program. The filing preserves continuity, not momentum: Harvey agreed to keep supplying Anteris for four additional months after the agreement’s initial term ended on May 24, 2026. 〔0〕 That avoids an immediate interruption to a supplier relationship tied to the company’s product-development and manufacturing effort, but it does not establish a durable long-term arrangement or add new economics.
Most of the news was already known: Anteris had previously disclosed that the Harvey agreement expired in May 2026 and that Harvey would continue supplying for four months if the agreement was not extended. The 8-K therefore formalizes the expected contingency almost at the end of that bridge period rather than changing the company’s commercial or clinical trajectory.
Bottom line: This is operationally useful but strategically routine: DurAVR’s supply line remains intact, while the filing leaves the longer-term supply question unresolved and adds little beyond prior disclosure. 〔1〕
Read the original 8-K on SEC EDGAR ↗